MGTA Stock: 51.66% Surge Explained

Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%

Magenta Therapeutics Trims R&D, Cuts Workforce

34,200 Shares in Magenta Therapeutics Inc (NASDAQ:MGTA) Acquired by Tudor Investment Corp Et Al

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA | MarketScreener

Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones

New milestone for Hrvatski Telekom

Magenta Therapeutics Inc (NASDAQ:MGTA) Shares Purchased by Geode Capital Management LLC

Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development

Magenta Therapeutics Inc (NASDAQ:MGTA) Expected to Announce Earnings of -$0.61 Per Share

The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Galaxy S20 on T-Mobile: Everything you need to know